These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 26863533)
21. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
22. Potentiation of mutant CFTR Cl- channel currents by the naturally occurring stilbene compound resveratrol. Yu B; Zhang Y; Sui Y; Yang S; Luan J; Wang X; Ma T; Yang H Pharmazie; 2013 Nov; 68(11):877-81. PubMed ID: 24380236 [TBL] [Abstract][Full Text] [Related]
23. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect. Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400 [TBL] [Abstract][Full Text] [Related]
24. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor). Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939 [TBL] [Abstract][Full Text] [Related]
25. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. Yang H; Shelat AA; Guy RK; Gopinath VS; Ma T; Du K; Lukacs GL; Taddei A; Folli C; Pedemonte N; Galietta LJ; Verkman AS J Biol Chem; 2003 Sep; 278(37):35079-85. PubMed ID: 12832418 [TBL] [Abstract][Full Text] [Related]
26. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242 [TBL] [Abstract][Full Text] [Related]
27. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Phuan PW; Yang B; Knapp JM; Wood AB; Lukacs GL; Kurth MJ; Verkman AS Mol Pharmacol; 2011 Oct; 80(4):683-93. PubMed ID: 21730204 [TBL] [Abstract][Full Text] [Related]
28. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. Pedemonte N; Lukacs GL; Du K; Caci E; Zegarra-Moran O; Galietta LJ; Verkman AS J Clin Invest; 2005 Sep; 115(9):2564-71. PubMed ID: 16127463 [TBL] [Abstract][Full Text] [Related]
29. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
30. Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Ai T; Bompadre SG; Wang X; Hu S; Li M; Hwang TC Mol Pharmacol; 2004 Jun; 65(6):1415-26. PubMed ID: 15155835 [TBL] [Abstract][Full Text] [Related]
32. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708 [TBL] [Abstract][Full Text] [Related]
33. The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. Mall M; Kreda SM; Mengos A; Jensen TJ; Hirtz S; Seydewitz HH; Yankaskas J; Kunzelmann K; Riordan JR; Boucher RC Gastroenterology; 2004 Jan; 126(1):32-41. PubMed ID: 14699484 [TBL] [Abstract][Full Text] [Related]
34. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. Bali V; Lazrak A; Guroji P; Fu L; Matalon S; Bebok Z FASEB J; 2016 Jan; 30(1):201-13. PubMed ID: 26336913 [TBL] [Abstract][Full Text] [Related]
35. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator. Luciani A; Villella VR; Esposito S; Gavina M; Russo I; Silano M; Guido S; Pettoello-Mantovani M; Carnuccio R; Scholte B; De Matteis A; Maiuri MC; Raia V; Luini A; Kroemer G; Maiuri L Autophagy; 2012 Nov; 8(11):1657-72. PubMed ID: 22874563 [TBL] [Abstract][Full Text] [Related]
36. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489 [TBL] [Abstract][Full Text] [Related]
37. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Andersson C; Roomans GM Eur Respir J; 2000 May; 15(5):937-41. PubMed ID: 10853862 [TBL] [Abstract][Full Text] [Related]
38. Annexin A5 increases the cell surface expression and the chloride channel function of the DeltaF508-cystic fibrosis transmembrane regulator. Le Drévo MA; Benz N; Kerbiriou M; Giroux-Metges MA; Pennec JP; Trouvé P; Férec C Biochim Biophys Acta; 2008 Oct; 1782(10):605-14. PubMed ID: 18773956 [TBL] [Abstract][Full Text] [Related]
39. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Brewington JJ; McPhail GL; Clancy JP Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802 [TBL] [Abstract][Full Text] [Related]
40. A domain mimic increases DeltaF508 CFTR trafficking and restores cAMP-stimulated anion secretion in cystic fibrosis epithelia. Clarke LL; Gawenis LR; Hwang TC; Walker NM; Gruis DB; Price EM Am J Physiol Cell Physiol; 2004 Jul; 287(1):C192-9. PubMed ID: 15028554 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]